![]() |
APLS | Apellis Pharmaceuticals, Inc. |
Pharmaceutical Preparations |
Book value per $ invested | $ 0.06 |
Leverage | 80.97% |
Market Cap | $ 2.8B |
PE | 0.00 |
Dividend Yield | 0.00% |
Profit | $ -227.8m |
Margin | -30.34% |
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.